Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07347249 | A Clinical Study to Assess Sutacimig in Participants With Congenital Factor VII Deficiency | PHASE2 | RECRUITING | 18 | — | — | Mar 11, 2026 | Jul 1, 2026 | May 29, 2026 | 1 | United Kingdom |
| Arm | Type | Description |
|---|---|---|
| Participants with a FVII(a) level of < 10% | EXPERIMENTAL | - |
| Participants with a FVII(a) level of ≥10% | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Sutacimig | DRUG | Sutacimig is a subcutaneously administered, bispecific antibody being developed as a prophylactic treatment option for congenital bleeding disorders. |
Inclusion Criteria: 1. Age 18 to 60 years, inclusive, at the time of signing informed consent. 2. Diagnosis of FVIID defined by Factor VII:C activity \< 10% documented on ≥ 2 different laboratory measurements by local laboratory assessment. 3. Severe bleeding history characterized by history of a m...